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Deregulated expression of heat shock proteins (HSPs) encoding genes is frequent in multiple myeloma. HSPs,
which are molecular chaperones involved in protein homeostasis pathways, have emerged recently as promising
therapeutic targets. Using human myeloma cell lines and primary myeloma cells belonging to various molecular
groups, we tested the efficacy of HSP90, HSP70, and heat shock factor 1 (HSF1) inhibitors alone or associated
with current antimyeloma drugs. We report here that KNK-437 (an inhibitor of HSF1) and bortezomib have additive effects
on apoptosis induction in cells belonging to groups with bad prognosis.
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Deregulated expression of heat shock proteins (HSPs)
and heat shock transcription factor 1 (HSF1) plays a
major role in the pathogenesis of multiple myeloma
(MM) [1,2]. In turn, several HSP/HSF1 inhibitors are
currently undergoing preclinical and/or clinical investi-
gations [3,4].
We used human myeloma cell lines (HMCLs) belonging
to several molecular groups [5,6] to analyze HSP expres-
sion (Figure 1A). HSP90 and its co-chaperone HSP70
were constitutively expressed in all HMCLs. HSP27 ex-
pression was more heterogeneous. Using the Little Rock
public database [6], we investigated whether the expres-
sion of HSPB1, HSPA4, and HSP90AA1 genes varied ac-
cording to the MM molecular classification. Compared to
normal bone marrow plasma cells, HSP genes were con-
stantly overexpressed (Figure 1B). HSPB1 and HSP90AA1
expressions were higher in the groups with bad prognosis,
PR/MS/MF, and HSPA4 expression in the HY/MF/PR
groups. The material and methods used in the study are
detailed in Additional file 1.
We studied the sensitivity of HMCLs towards 17-AAG
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unless otherwise stated.and, in turn, of both HSP70 and HSP27). HMCLs were
constantly sensitive to both inhibitors although heteroge-
neously responding (Figure 1C, Additional files 2 and 3).
This suggests that inhibiting HSPs might potentiate drug
treatments for MM patients.
HSPs contribute to MM survival by impairing the
mitochondria- and endoplasmic reticulum (ER)-mediated
apoptotic pathways [7,8]. In L363 cells (MF group), HSP70
expression decreased following KNK-437 treatment while
increased after 17-AAG (Figure 1D). As confirmed by the
activation of procaspases 9 and 3 and the cleavage of
PARP, a mitochondrial-mediated apoptosis was triggered.
The expression of anti-apoptotic BCL2 and MCL1 pro-
teins decreased after KNK-437 treatment. Last, both
inhibitors induced a decrease of the procaspase 4, thus fa-
voring an ER stress.
We investigated the capacity of HSP90/HSF1 inhibi-
tors to co-operate with common antimyeloma drugs
(bortezomib, dexamethasone, or lenalidomide). We cal-
culated the combination index using the method of
Chou [9]. Both inhibitors antagonized lenalidomide ef-
fects, suggesting that those associations could be harm-
ful (Additional file 4). The combination of KNK-437
with bortezomib or dexamethasone was highly potent in
all cell lines tested but not the association 17-AAG/l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 HSP90 and HSF1 inhibitors are potent antimyeloma drugs. (A) HSP expression was determined in a panel of HMCLs belonging to CD-1/2,
MS, and MF groups ([5] and Additional file 2) by Western blotting. Blots were incubated with the following Abs: anti-HSP27, −HSP70, and -HSP90 from
Santa Cruz Biotech.; anti-GAPDH from Life Technologies; and α-tubulin from Dako. Abs anti-GAPDH and -α-tubulin served for gel loading
control. (B) Affymetrix gene expression profiles of purified myeloma cells (Additional file 1). HSP90AA1, HSPB1, and HSPA4 gene expressions
(in Affymetrix signal units) are indicated for each patient in the different molecular groups according to [6]: HY, CD-1/2, LB corresponding to standard risk
in light gray, MS, or MF, and PR corresponding to high risk in dark gray. The expression of those genes was also analyzed in normal bone marrow plasma
cells (BMPC). p< 0.001 and NS (not significant) with Student’s t test. (C) The cell lines used in this assay are described in Additional file 1. Cells (0.5 × 106/ml)
were seeded for 48 h in 96-well plates and treated with serial dilutions of 17-AAG (20 to 0.3 μM) or KNK-347 (200 to 3.1 μM). Cell death was then assessed
using flow cytometry with the combined analysis of APO2.7 (Beckman Coulter) staining according to the manufacturer’s recommendation
and the altered cellular morphology characteristics of apoptosis (lower FSC-H and higher SSC-H). Flow cytometry analysis was performed
on a FACSCalibur using the CellQuest software (BD Biosciences). The LD50 was defined as the concentration that killed 50% of cells (mean
of 3 experiments). (D) L363 cells were treated for 24 h with 100 μM KNK-437 or 5 μM 17-AAG. Western blots were obtained as before. Ab anti-MCL1 was
obtained from Santa Cruz Biotech. and anti-BCL2 from Dako (Glostrup, Denmark). The cleaved forms of PARP and procaspase 3 are arrowed.▲ marked a
non-specific band.
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the decrease of MCL1 and BCL2 levels were enhanced
by the association KNK-437/bortezomib but not the as-
sociation 17-AAG/bortezomib (Figure 2A). VER-155008,
a strict HSP70 inhibitor, combined with bortezomib was
no more potent for inducing apoptosis (Figure 2B).
We tested the response of HMCLs co-cultured with
human bone marrow stromal cells (HS-5 cells). The per-
centage of apoptotic cells was enhanced by the co-
treatment KNK-437/bortezomib (Figure 2B). This indi-
cates that KNK-437/bortezomib combined therapy could
overcome cell adhesion-mediated drug resistance.We finally analyzed the response of primary cells isolated
from four MM or plasma cell leukemia (PCL) patients
(Additional file 5) towards KNK-437 and bortezomib
after CD138 staining [10]. For patient #3, the fraction
of CD138+ cells decreased in the presence of both drugs,
revealing an additive effect in primary cells (Figure 2C).
Similar results were obtained for other MM primary sam-
ples (Additional file 6).
Our results strongly suggest that HSF1 inhibitors might
be promising agents in association with bortezomib-based
therapeutic protocols to treat MM patients with adverse
prognosis or in relapse.
Figure 2 Inhibitors of HSP90 and HSF1 co-operate differently with antimyeloma drugs. (A) LP1 MM cells were treated with 10 μM KNK-437 or
100 nM 17-AAG or/and 10 nM bortezomib. Whole cell extracts were analyzed as before by Western blots with the indicated Abs. Anti-GAPDH
Ab controlled gel loading. ▲ marked an unspecific band. (B) L363, LP1, and 8,226 cells were cultured on HS-5 cells 24 h before being treated
as previously, stained with anti-APO2.7-PE recognizing specifically apoptotic cells followed by flow cytometry analysis (Gallios, Beckman Coulter). Means
and SD of three independent experiments are presented in histograms. *p < 0.05, **p < 0.01, ns, not significant with Student’s t test. (C) Primary cells
from patient #3 were treated with vehicle or bortezomib (5 or 10 nM) or KNK-437 (10 or 50 μM) for 24 h and then analyzed for CD138 labeling (FL2) as
described [10]. Cell death was determined by the percentage of CD138+ cells that have lost CD138 expression. The percentage of living cells (CD138+)
for each culture condition is indicated on the graph. At least 2 × 104 events were gated for each culture condition with the FACsCalibur cytometer; data
were analyzed with the CellQuest software.
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Additional file 1: Material and methods used in the study. The file
contains data on cell line cultures, treatments, and proliferation measurement;
primary samples, treatments, and CD138 expression analyses; and gene
expression profiling.
Additional file 2: Response towards HSP90 and HSF1 inhibitors in a
panel of MM cell lines. Cells (0.5 × 106 cells/ml) were seeded for 48 h in
96-well plates and treated with increasing concentrations of 17-AAG (0.3to 20 μM) or KNK-347 (3.1 to 200 μM). Cell death was measured by
APO2.7 staining and cytometry sorting. LD50 values were defined as the
dose that killed 50% of cells. Data represent the mean and SD of three
experiments.
Additional file 3: Inhibitors of HSP90 and HSF1 co-operate differently
with antimyeloma drugs in various HMCLs. Cells were treated for 24 h
with HSP inhibitors and then with dexamethasone (Dex), bortezomib
(Bort) or lenalidomide (Len) for additional 24 h at the concentrations
indicated or with vehicle (DMSO). The absorbance (OD at 490 nm) of
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corresponding clone treated with vehicle (ratio defined as 1 arbitrary unit, AU).
For each set of culture conditions, the mean of triplicate ratios is indicated on
the graph, together with the SD.
Additional file 4: Interactions between the drugs analyzed by the
combination index (CI) method. HMCLs were treated for 24 h with
HSP90 or HSF1 inhibitors and with dexamethasone, bortezomib, or
lenalidomide for additional 24 h at the indicated concentrations. Cell
viability was then determined by MTT assay. CIs were calculated according
to Chou [9]. CI < 1 indicates synergy; CI = 1, additive effect; CI > 1,
antagonism (gray boxes).
Additional file 5: Clinical characteristics of MM/PCL patients.
Samples were obtained from patients at diagnosis (D) or relapse (R);
patients had multiple myeloma (MM), primary plasma cell leukemia
(pPCL), or secondary plasma cell leukemia (sPCL).
Additional file 6: Additivity of bortezomib and KNK-347 co-treatment
on MM primary samples. Primary cells were obtained from patients with
MM or PCL. Purified CD13+ cells were cultured for 24 h and then treated
with 5 nM bortezomib alone or in combination with 10 μM KNK-437. Cell
death was determined as the percentage of CD138+ cells that have lost
CD138. The percentage of dead cells directly measured (observed) and the
percentage of dead cells calculated for an additive effect (expected) were not
significantly different (p= 0.37, Wilcoxon matched-pairs signed-rank test). This
signifies that the effect of the combination of both drugs was indeed additive.
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